Meghan E McGarry1, John M Neuhaus2, Dennis W Nielson1, Esteban Burchard3,4, Ngoc P Ly1. 1. Department of Pediatrics, University of California, San Francisco, California. 2. Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California. 3. Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, California. 4. Department of Medicine, University of California, San Francisco, California.
Abstract
BACKGROUND: Hispanic patients with cystic fibrosis (CF) have decreased life expectancy compared to non-Hispanic white patients. Pulmonary function is a main predictor of life expectancy in CF. Ethnic differences in pulmonary function in CF have been understudied. The objective was to compare longitudinal pulmonary function between Hispanic and non-Hispanic white patients with CF. METHODS: This cohort study of 15 018 6-25 years old patients in the CF Foundation Patient Registry from 2008 to 2013 compared FEV1 percent predicted and longitudinal change in FEV1 percent predicted in Hispanic to non-Hispanic white patients. We used linear mixed effects models with patient-specific slopes and intercepts, adjusting for 14 demographic and clinical variables. We did sub-analyses by CFTR class, F508del copies, and PERT use. RESULTS: Hispanic patients had lower FEV1 percent predicted (79.9%) compared with non-Hispanic white patients (85.6%); (-5.8%, 95%CI -6.7% to -4.8%, P < 0.001), however, there was no difference in FEV1 decline over time. Patients on PERT had a larger difference between Hispanic and non-Hispanic white patients in FEV1 percent predicted than patients not on PERT (-6.0% vs -4.1%, P = 0.02). The ethnic difference in FEV1 percent predicted was not statistically significant between CFTR classes (Class I-III: -6.1%, Class IV-V: -5.9%, Unclassified: -5.7%, P > 0.05) or between F508del copies (None: -7.6%, Heterozygotes: -5.6%, Homozygotes: -5.3%, P > 0.05). CONCLUSIONS: Disparities in pulmonary function exist in Hispanic patients with CF early in life and then persist without improving or worsening over time. It is valuable to investigate the factors contributing to pulmonary function in Hispanic patients with CF.
BACKGROUND: Hispanic patients with cystic fibrosis (CF) have decreased life expectancy compared to non-Hispanic whitepatients. Pulmonary function is a main predictor of life expectancy in CF. Ethnic differences in pulmonary function in CF have been understudied. The objective was to compare longitudinal pulmonary function between Hispanic and non-Hispanic whitepatients with CF. METHODS: This cohort study of 15 018 6-25 years old patients in the CF Foundation Patient Registry from 2008 to 2013 compared FEV1 percent predicted and longitudinal change in FEV1 percent predicted in Hispanic to non-Hispanic whitepatients. We used linear mixed effects models with patient-specific slopes and intercepts, adjusting for 14 demographic and clinical variables. We did sub-analyses by CFTR class, F508del copies, and PERT use. RESULTS: Hispanic patients had lower FEV1 percent predicted (79.9%) compared with non-Hispanic whitepatients (85.6%); (-5.8%, 95%CI -6.7% to -4.8%, P < 0.001), however, there was no difference in FEV1 decline over time. Patients on PERT had a larger difference between Hispanic and non-Hispanic whitepatients in FEV1 percent predicted than patients not on PERT (-6.0% vs -4.1%, P = 0.02). The ethnic difference in FEV1 percent predicted was not statistically significant between CFTR classes (Class I-III: -6.1%, Class IV-V: -5.9%, Unclassified: -5.7%, P > 0.05) or between F508del copies (None: -7.6%, Heterozygotes: -5.6%, Homozygotes: -5.3%, P > 0.05). CONCLUSIONS: Disparities in pulmonary function exist in Hispanic patients with CF early in life and then persist without improving or worsening over time. It is valuable to investigate the factors contributing to pulmonary function in Hispanic patients with CF.
Keywords:
cystic fibrosis (CF); epidemiology; healthcare disparities; hispanic latino; pulmonary function testing (PFT); social dimensions of pulmonary medicine
Authors: Gerald T O'Connor; Hebe B Quinton; Richard Kahn; Priscilla Robichaud; Joanne Maddock; Thomas Lever; Mark Detzer; John G Brooks Journal: Pediatr Pulmonol Date: 2002-02
Authors: C Schaedel; I de Monestrol; L Hjelte; M Johannesson; R Kornfält; A Lindblad; B Strandvik; L Wahlgren; L Holmberg Journal: Pediatr Pulmonol Date: 2002-06
Authors: R J Kuczmarski; C L Ogden; L M Grummer-Strawn; K M Flegal; S S Guo; R Wei; Z Mei; L R Curtin; A F Roche; C L Johnson Journal: Adv Data Date: 2000-06-08
Authors: Michael W Konstan; Steven M Butler; Mary Ellen B Wohl; Marcia Stoddard; Robert Matousek; Jeffrey S Wagener; Charles A Johnson; Wayne J Morgan Journal: J Pediatr Date: 2003-06 Impact factor: 4.406
Authors: Andrew M Zeiger; Meghan E McGarry; Angel C Y Mak; Vivian Medina; Sandra Salazar; Celeste Eng; Amy K Liu; Sam S Oh; Thomas J Nuckton; Deepti Jain; Thomas W Blackwell; Hyun Min Kang; Goncalo Abecasis; Leandra Cordero Oñate; Max A Seibold; Esteban G Burchard; Jose Rodriguez-Santana Journal: Pediatr Pulmonol Date: 2019-10-30
Authors: Gregory S Sawicki; Kate Van Brunt; Jason Booth; Evan Bailey; Stefanie J Millar; Michael W Konstan; Patrick A Flume Journal: J Cyst Fibros Date: 2021-07-19 Impact factor: 5.527